World Cancer Day 2025

Written by Kimo Sanderson

Every year on February 4th, #WorldCancerDay is led by Union for International Cancer Control (UICC). With this global initiative they strive to raise awareness, improve education, and ignite government action in the fight against cancer. By raising worldwide awareness with campaigns like #IAmAndIWill. The UICC is reimagining a world where cancer is preventable and access to life-saving treatments is equal for everyone everywhere. 

While there is much work to be done to manifest the UICC vision, Hapatune wishes to recognize some of the most recent oncology drug approvals by the FDA:

• In January 2025, Amgen was granted approval for sotorasib (LUMAKRAS®) in combination with panitumumab (Vectibix®) for KRAS G12C-mutated colorectal cancer.
  
• In January 2025, AstraZeneca was granted traditional approval to acalabrutinib (Calquence®) with bendamustine and rituximab for adults with previously untreated mantle cell lymphoma (MCL).
  
• In August 2024, Citius Pharmaceuticals received approval for LYMPHIR™ (denileukin diftitox-cxdl), a novel immunotherapy for the treatment of r/r cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy.
  
• Lovance Biotherapeutics was granted approval of Lifileucel (Amtagvi®) in February 2024 for unresectable or metastatic melanoma. This was the first treatment for cancer that uses immune cells called tumor-infiltrating lymphocytes, or TILs.
  

Together, let’s work to create a world without cancer!